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Cardiac embolism is the most fre-
quent cause of ischaemic stroke in
hospital-based and population-based
registers. Patent foramen ovale (PFO)
with and without atrial septal
aneurysm (ASA) has been recognised
as a potential risk factor for
ischaemic stroke. Besides paradoxical
embolism from small thrombi that
arise in the venous system and car-
diac thrombus formation secondary to
PFO/ASA-related cardiac arrhythmia,
another likely ischaemic stroke cause
is thrombus formation in the PFO.
Several studies have investigated a
possible link between PFO and
migraine. Del Sette et al. compared 44
patients with migraine with aura, 73
patients less than 50 years of age with
focal cerebral ischaemia, with 50 con-
trol individuals without cerebrovascu-
lar disease or migraine using transcra-
nial Doppler [1]. The prevalence of
right-to-left shunt was significantly
higher in patients with migraine with
aura (41%) and cerebral ischaemia
(35%) than in controls (8%). Anzola
and colleagues performed a case-con-
trol study of 113 consecutive patients
with migraine with aura, 53 patients
with migraine without aura and 25
age-matched nonmigraine individuals
[2] The prevalence of PFO was signif-
icantly higher in patients with
migraine with aura (48%) compared
with patients with migraine without
aura (23%) and controls (20%). A
number of other studies confirmed by
different methods (transcranial
Doppler, transoesophageal echocardio-
graphy) the relationship between PFO
and migraine with aura [3, 4]. There
seems to be a much weaker associa-
tion with migraine without aura and
other headaches. A possible explana-
tion might be that both conditions,
migraine with aura and PFO, could be
dominantly inherited and share a com-
mon genetic background [5].
A coincidence of two conditions,
however, does not necessarily imply
a causal relationship. Moreover, it is
difficult to imagine how PFO could
lead to a migraine attack with aura –
a neural event in the occipital cortex
caused by spreading depression. Even
if small emboli arise from a PFO,
these would travel preferentially into
the anterior circulation rather than
into the posterior cerebral artery.
Should PFOs be closed in patients
with migraine? Even if we assume
there is a causal relationship between
PFO and migraine, closure of PFO
should then result in migraine
improvement. To date, only one ran-
domised and controlled prospective
trial has been performed in the UK.
The MIST trial is not yet published,
but the results were reported at an
international meeting. This trial
recruited patients with frequent
migraine with aura refractory to pre-
ventive treatment (although topira-
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mate and lamotrigine were not used
[6, 7]). The trial randomised 147
patients to either transcutaneous PFO
closure with the STARFlex device or
a sham procedure. One hundred and
thirty-five patients completed the trial
after 6 months. The primary endpoint,
cure of migraine, was not significant-
ly different between the 2 treatment
groups. There was a trend for a reduc-
tion of migraine frequency in the
operated group, which is not signifi-
cant if one corrects for the imbalance
in migraine frequency at baseline. The
procedure was associated with some
serious adverse events e.g., pericar-
dial tamponade, pericardial effusion,
retroperitoneal bleed, atrial fibrillation
and chest pain. AEs in the sham group
included incision site bleed, anaemia,
nose bleed and a brainstem stroke.
In a retrospective study, 215
stroke patients with PFO were exam-
ined and underwent closure of PFO as
a secondary prevention measure [8].
A year later, patients were asked
about their migraine frequency before
and after PFO closure to determine
whether this intervention affected
migraine attacks. Patients with a PFO
and a history of stroke had higher
migraine prevalence (22%) than the
general population (10%). In patients
with migraine with aura, percutaneous
PFO closure reduced the frequency of
migraine attacks by 54% (1.2±0.8 vs.
0.6±0.8 per month; p=0.001) and in
patients with migraine without aura
by 62% (1.2±0.7 vs. 0.4±0.4 per
month; p=0.006). PFO closure did not
have a statistically significant effect
on headache frequency in patients
with nonmigraine headaches. Several
other retrospective studies found a
similar relationship between PFO clo-
sure and migraine improvement
[9–14]. However, with one exception,
all these studies had major limita-
tions. First, despite migraine improv-
ing spontaneously with age, no study
had a control group. Second, the high
placebo response can reduce the fre-
quency of migraine by up to 70%.
Third, after PFO closure, most
patients received aspirin, which has a
modest migraine prophylactic activity,
at least in men [15, 16]. Clopidogrel,
given as an aspirin alternative, might
also reduce migraine frequency [17,
18]. Fourth, retrospective collection
of headache data is highly unreliable;
recall bias has a major influence on
the results. Furthermore, the most
recent study observed that as many
patients improve from migraine as
develop new onset migraine after
PFO closure [11].
Thus, to date there is insufficient
evidence on the hypothesis that
migraine frequency is improved by
PFO closure. Additional properly
conducted, prospective studies in
migraine patients including control
groups with other or no headaches
are needed. These are underway in
Europe and the USA. Until then PFO
closure should not be used for the
prophylaxis of migraine.
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